Kim M. Pfotenhauer, DO

By the end of this module, you should be able to:

• Identify the classification of diabetes including type 1, type 2, atypical and gestational diabetes
• Describe methods for diagnosis of prediabetes and diabetes
• Apply recommendations for screening for prediabetes and diabetes to patients

Kevin T. Miller, DO

By the end of this module, you should be able to:

• Define the condition of prediabetes
• Understand the disease burden in our population 
• Analyze the progression of glucose impairment to T2D
• Apply the standards for identification of persons with prediabetes
• Examine the data for prediabetes disease intervention
• Create an individualized care plan for each person with prediabetes 

Elizabeth M. Venditti, PhD

By the end of this module, you should be able to:

• Outline key lifestyle behaviors (nutrition, physical activity, weight) that play a critical role in the development of Prediabetes (PreD) and Type 2 Diabetes (T2D)
• Summarize biobehavioral relationships of these lifestyle factors with PreD and T2D course and outcomes focusing on midlife to late life adults
• Review evidence supporting efficacy and effectiveness of lifestyle modification programs and disease prevention or management
• Recognize barriers and facilitators. 
• Discuss promising new directions.

Jay H. Shubrook, DO, FAAFP, FACOFP

By the end of this module, you should be able to:

• Apply SDOH to diabetes
• Through patient interactions,
  • Identify SDOH factors
  • Discuss SDOH with patients
  • Include SDOH in treatment plans
• Provide patients with supportive resources

John L. Leahy, MD

By the end of this module, you should be able to:

• Relate insulin therapy to the 24-hour pattern of endogenous insulin secretion. 
• Differentiate the pharmacokinetic profiles of action of available short-acting (bolus) and long-acting (basal) insulins.
• Interpret the clinical application of insulin concentration U numbers and biosimilar insulins.
• Summarize the key steps in optimizing use of basal and bolus insulin in type 2 diabetes mellitus.
• Recognize the clinical differences and relative benefits of insulin versus GLP-1 receptor agonist therapy in type 2 diabetes.  

Lawrence Blonde, MD, FACP, MACE

By the end of this module, you should be able to:

• Identify non-insulin antihyperglycemic agents presently available for treatment of individuals with type 2 diabetes
• Compare and contrast benefits and risks of non-insulin antihyperglycemic agents including those not specifically related to glucose lowering
• Select appropriate antihyperglycemic agents for individual patients based on matching characteristics of medications and patients’ needs

Eden M. Miller, DO

By the end of this module, you should be able to:

• Identify essential diabetes disease state elements as a foundation 
• Prescribe science-based individualized care plans
• Create an effective diabetes care team to improve clinic workflow, coordination and facilitate engagement 
• Conduct the “Diabetes Only” visit to reduce therapeutic inertia and optimal timeframe for scheduling follow-up visits based on A1C and medication changes
• Understand virtual care to facilitate touch points and more convenient interactions

Anne L. Peters, MD

By the end of this module, you should be able to:

• Define the limits of the A1C and BGM
• Describe the various types of technology available to manage people with diabetes
• Explain how to choose the right technology for each individual

Leonard Bertheau, DO

By the end of this module, you should be able to:

• Identify different approaches to care delivery
• Understand methods that have worked in group visits, case studies, and remote visits
• Analyze effective two-way email communications
• Recognize hurdles for primary care physicians

Davida F. Kruger, MSN, APN-BC,BC-ADM

By the end of this module, you should be able to:

• Describe the potential major complications of type 2 Diabetes
• Explain the importance of assessing the patient with type 2 diabetes for potential complications
• Describe the interventions needed to prevent the risk of complications of type 2 Diabetes
• Apply current screening recommendations to ensure patients receive timely care

Robert S. Gotfried, DO, FAAFP

By the end of this module you should be able to:

• Recognize the emotional impact of having diabetes mellitus (DM)
• Identify the psychiatric conditions commonly seen in persons with diabetes (PWD)
• Recognize diabetes distress (DD)
• Summarize the contributing psychosocial factors
• Utilize patient-centered tools
• Promote effective coping and patient empowerment

Mark E. Molitch, MD

By the end of this module, you should be able to:

• Identify how certain conditions can influence glycemic goals and treatment strategies in patients with diabetes
• Identify how age and frailty influence glycemic goals and choice of therapy in older patients with diabetes
• Identify how chronic kidney disease (CKD) affects diabetes control and the metabolism of various medications used for diabetes
• Recognize the benefits of SGLT2 inhibitors and GLP-1 receptor agonists on kidney and cardiovascular disease in patients with diabetes
• Recognize how diabetes medications affect body weight in overweight/obese individuals with diabetes